Delcath Systems Inc.: Clinical Trials

13 trials sponsored by Delcath Systems Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 3 completed, 2 unknown, 1 active not recruiting. 8 Phase 2, 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Recruiting 4, Completed 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 34Completed 2, Active not recruiting 1, Unknown 1
Phase 11Recruiting 1

Follow Delcath Systems Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases
Phase 1 / Phase 2RecruitingUniversity of Wisconsin, Madison152026-11-012026-10-30
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) - Metastatic Breast Cancer in the Liver
Phase 2RecruitingDelcath Systems Inc.902026-01-292026-10-19
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp - Metastatic Uveal Melanoma
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute182025-12-312026-03-31
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone - Refractory Metastatic Colorectal Cancer
Phase 2RecruitingDelcath Systems Inc.902025-08-052026-10-20
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) - Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Phase 3Active not recruitingDelcath Systems Inc.302022-06-102023-12-21
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Melphalan/HDS, Cisplatin and Gemcitabine - Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
Phase 2 / Phase 3UnknownDelcath Systems Inc.2952018-04-102022-03-24
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Melphalan/HDS - Ocular Melanoma, Uveal Melanoma
Phase 3CompletedDelcath Systems Inc.1022016-02-012026-09-10
Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy
Hepatic Malignant Neoplasm Primary Non-Resectable
UnknownDelcath Systems Inc.2002016-01-142018-09-11
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Melphalan/HDS, Sorafenib - Hepatocellular Carcinoma (HCC)
Phase 2WithdrawnDelcath Systems Inc.2014-10-012017-12-18
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Delcath Hepatic Delivery System, Melphalan - Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Phase 2TerminatedDelcath Systems Inc.172014-06-012022-10-17
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
melphalan, regional chemotherapy, systemic chemotherapy - Intraocular Melanoma, Melanoma (Skin)
Phase 3CompletedDelcath Systems Inc.932006-02-012021-06-21
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
isolated perfusion, melphalan - Cancer
Phase 2CompletedDelcath Systems Inc.562004-09-012013-10-23
Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
Melphalan, Percutaneous Hepatic Perfusion - Metastatic Liver Cancer, Ocular Melanoma
No longer availableDelcath Systems Inc.2013-10-23

Conditions studied

Uveal Melanoma (6)  ·  Melanoma (4)  ·  Carcinoma, Hepatocellular (3)  ·  Bile Duct Neoplasms (2)  ·  Cholangiocarcinoma (2)  ·  Rectal Neoplasms (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Appendiceal Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Islet Cell (1)  ·  Carcinoma, Medullary (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Gallbladder Neoplasms (1)

Interventions

Melphalan (7)  ·  Bevacizumab (1)  ·  Capecitabine (1)  ·  Chemotherapy, Cancer, Regional Perfusion (1)  ·  Cisplatin (1)  ·  Gemcitabine (1)  ·  Neoadjuvant Therapy (1)  ·  Nivolumab (1)  ·  Opdualag (1)  ·  Sorafenib (1)  ·  Vinorelbine (1)  ·  eribulin (1)  ·  relatlimab (1)  ·  tebentafusp (1)  ·  trifluridine tipiracil drug combination (1)

Countries

United States (11)  ·  United Kingdom (4)  ·  Germany (3)  ·  Italy (3)  ·  Spain (2)  ·  Austria (1)  ·  Belgium (1)  ·  Czechia (1)  ·  France (1)  ·  Netherlands (1)  ·  Serbia (1)  ·  Sweden (1)  ·  Switzerland (1)  ·  Turkey (Türkiye) (1)

Top investigators

Jonathan Zager, MD (2)  ·  Charles W Nutting, DO (1)  ·  Eric D Whitman, MD (1)  ·  H. Richard Alexander, MD (1)  ·  James F Pingpank, MD (1)  ·  Johnny John, MD (1)  ·  Jonathan Zager, MD, FACS (1)  ·  Leslie Callahan, RN (1)  ·  Mark Faries, MD (1)  ·  Marwan Fakih, MD (1)  ·  Marybeth Hughes, MD (1)  ·  Marybeth S. Hughes, MD (1)  ·  Vincent Ma, MD (1)

Results publications

PMID 38704501